The ILLUMINATE Phase 2 study (NCT03994393) is evaluating the safety and tolerability of combined durvalumab and tremelimumab plus platinum-pemetrexed in EGFRm NSCLC following progression on EGFR TKIs (75). Here, EGFR is linked to non-small cell lung carcinoma.